Suvi-Katri Leivonen

12PUBLICATIONS
29CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsPredictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 08, 2026
Folate receptor beta targeting of tumor-associated macrophages improves lymphoma cell responses to CD19 CAR T cells.

|Aug 07, 2025
Spatial Analysis of the Tumor Microenvironment in Diffuse Large B-cell Lymphoma Reveals Clinically Relevant Cell Interactions and Recurrent Cellular Neighborhoods.

Matias Autio, Suvi-Katri Leivonen, Leo Meriranta

|Jan 27, 2023
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.

Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto

|Sep 02, 2022
Low lymphocyte-to-monocyte ratio predicts poor outcome in high-risk aggressive large B-cell lymphoma.

Heli Vajavaara, Suvi-Katri Leivonen, Judit Jørgensen

|Dec 23, 2021
Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients.

Kristiina Karihtala, Suvi-Katri Leivonen, Marja-Liisa Karjalainen-Lindsberg

|Dec 15, 2021
Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment.

Matias Autio, Suvi-Katri Leivonen, Oscar Brück

Pageof 2

Frequent Collaborators

10 joint publications

Sirpa Leppä

3 joint publications

Teijo Pellinen

2 joint publications

Heli Vajavaara

1 joint publications

Alejandra Cervera